TRE-515 has received FDA fast track designation for treating PSMA-positive mCRPC, aiming to accelerate its development and availability. The drug is being tested in combination with Pluvicto, a ...
In this context, "claims evaluated" refers to how ProstAfense presents and explains its own formulation approach and ingredient structure, rather than a comparative or third-party product review.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results